Strengthening Collaboration with Overseas Bases and Global Corporate Functions
First written in FY2017. 6 of 7 entries say "Advanced", first in FY2023. Latest entry: FY2026.
The whole theme swung hardest in 2022: 1 of 7 companies on the "Worse" side.
11 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The mass spectrometry system jointly developed with customers at the North American R&D center increased in the clinical testing market.」
Collaboration between overseas bases and customers led to the business outcome of increased adoption in the clinical testing market of the mass spectrometry system jointly developed at the North American R&D Center. - 2026-05-21AdvancedGeneral Meetings of Shareholders
「In terms of development, we established a new site for the North America R&D Center in San Francisco, while in production, we launched a production site for turbomolecular pumps in China.」
The development of overseas sites was presented through the establishment of a new North America R&D Center site in San Francisco and the launch of a turbomolecular pump production site in China. - FY2026-H1AdvancedAnnual report
「The mass spectrometry system jointly developed with customers at the North American R&D Center is gaining traction in the clinical testing market.」
It is stated that the North American R&D center contributed to an increase in products for the clinical testing market through joint development with customers. - FY2025-H1AdvancedAnnual report
「In addition, to expand its overseas business, the company established an R&D center in North America and a sales subsidiary in Mexico for its analytical and medical equipment businesses, and」
The infrastructure supporting the overseas business has expanded from the establishment of a North American R&D center to the establishment of a Mexican subsidiary selling analytical and medical systems. - FY2024AdvancedAnnual report
「In healthcare, we aim to expand the business by making North America our primary focus region, using the R&D center opened in April 2024 to launch products and services that address the challenges faced by clinical and pharmaceutical customers.」
The North American R&D center opened in April 2024 as part of efforts to coordinate overseas locations and has progressed to the stage of being used as a development base for products and services for clinical and pharmaceutical applications. - FY2023AdvancedAnnual report
「In North America, we will establish a North American R&D Center to promote joint research and development with key customers possessing advanced LC and MS technologies. In addition, we will establish development centers on the East and West Coasts of the United States and expand our capabilities for developing methods in collaboration with customers in the pharmaceutical and other fields.」
Regarding coordination among overseas sites and strengthening company-wide functions, specific organizational measures were outlined, including the establishment of a North America R&D center and development centers on the East and West coasts of the United States. - FY2017First statedAnnual report
「We will deepen collaboration with overseas sites and strengthen the corporate functions required for global business development.」
First presentation as a standalone initiative of deeper collaboration with overseas sites and stronger corporate functions supporting global business.